Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THUMB: Trastuzumab Deruxtecan +/- Bevacizumab in HER2-low Breast Cancer with Brain Metastasis
NCT07150208Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Fudan University. Started Oct 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07150208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150208.